1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Abecma Approval In Earlier Myeloma Carries Caution On Early Death Data

 
• By Bridget Silverman

Labeling describes early death imbalance that delayed approval of Bristol Myers Squibb’s CAR-T therapy for more than three months after its user fee goal, but does not add to boxed warning; J&J’s Carvykti is due for imminent US FDA action on its own early-stage myeloma bid.

BMS (Bristol) building
• Source: Shutterstock

The US FDA’s concerns over early deaths associated with BCMA-targeted chimeric antigen receptor T-cell (CAR-T) therapy are being handled by labeling changes, including a new section in the Warning and Precautions section in the labeling for a new indication approved 4 April 2024 for Bristol Myers Squibb Company/2seventy Bio, Inc.’s B-cell maturation agent (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy Abecma (idecabtagene vicleucel).

Key Takeaways

  • Bristol Myers Squibb/2seventy bio’s Abecma approved for triple-class exposed multiple myeloma patients after two prior lines of therapy on 4 April 2024, moving use of the CAR-T therapy earlier than its original fifth-line-plus indication.

“A higher proportion of patients in the Abecma arm compared to the standard regimen’s arm died within the first 9...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

America Next: Most Novel Agents With July Goal Dates Have Been Approved Overseas

 
• By Bridget Silverman

The US FDA will not be in its usual position as the first regulator to approve novel drugs, with only one of the six novel candidates on the July user fee calendar seeking its first approval worldwide in the US

US FDA’s June Approval Forecast: Infection Prevention, Cancer And HAE

 
• By Bridget Silverman

Upcoming FDA user fee goal dates include novel products from a busy lung cancer pipeline, a single-dose passive immunization against RSV for infants, what could be the first oral HAE acute treatment, and a first-in-class HAE preventive antibody.

Keep Talking: US FDA’s Beleaguered Biologics Center Remains Vital To Regenerative Medicine

 
• By Bridget Silverman

Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.

Maybe In May: US FDA Calls Coming On Moderna Next-Gen COVID-19 Vaccine, AbbVie’s Big ADC Bet

 
• By Bridget Silverman

The 31 May goal date for Moderna’s next-generation COVID-19 vaccine looms over the month, but the US FDA's decision lineup includes three more novel agents, including AbbVie's Teliso-V antibody-drug conjugate, as well as supplemental indications like GSK's bid for Nucala in COPD.

More from Regulatory Trackers